
ProGen Intelligence | Radiopharma | November 2026
Will Ac-225 Replace Lu-177? What the Phase 3 Trials Are Actually Built For
Alpha emitters hit harder, so the common assumption is that actinium-225 drugs will push lutetium-177 out of the clinic. The trials that will shape the first Ac-225 approvals point to a different near-term picture: alpha arriving after beta, and the company that sells the leading beta drug running the largest trial that tests alpha earlier.

Byron Fitzgerald
Founder, ProGen Search
Key points
- We found four Ac-225 radioligand trials on ClinicalTrials.gov with a Phase 3 component (as of 20 November 2026): ACTION-1 (BMS / RayzeBio), VECTRA-01 (AstraZeneca), PSMAcTION (Novartis) and AcTFirst (Novartis).
- Three of the four enroll patients who have already had beta therapy. Two of those go further and screen out patients the beta therapy did not help early.
- The only one with a readout, ACTION-1, met its progression-free survival endpoint at a planned interim analysis (BMS, 12 October 2026). No effect size has been published.
- The fourth and largest, AcTFirst (940 patients planned), excludes prior radiopharmaceutical treatment, and one option in its control arm is Pluvicto, Novartis's own Lu-177 drug.
- ProGen reading: the first Ac-225 label is likely to sit after Lu-177, and for the rest of this decade alpha is more likely to add to Lu-177 demand than to cut it.
The assumption
Actinium-225 emits alpha particles: heavy, high-energy and short-range. Lutetium-177 emits beta particles, which travel further and deposit less energy along the way. That physics is why many people expect Ac-225 radioligands to become the stronger successor to today's Lu-177 drugs, Pluvicto in prostate cancer and Lutathera in neuroendocrine tumors.
Physics suggests what a drug might do. Trial eligibility helps define the population regulators may first consider for approval, so the trial designs are worth reading closely.
The four trials
Source: ClinicalTrials.gov records for ACTION-1, VECTRA-01, PSMAcTION and AcTFirst, 20 November 2026.
| Trial | Sponsor | Drug | Disease | Patients | Prior beta therapy | Est. primary completion |
|---|---|---|---|---|---|---|
| ACTION-1 (Phase 1b/3) | RayzeBio (BMS) | RYZ101, Ac-225, somatostatin receptor | Gastroenteropancreatic neuroendocrine tumors | 343 enrolled | Required: 2 to 4 cycles of Lu-177 SSA, at least 6 months of disease control, then progression | December 2026 |
| VECTRA-01 (Phase 3) | AstraZeneca | AZD2265 (FPI-2265), Ac-225-PSMA-I&T | Metastatic castration-resistant prostate cancer | 670 planned | Required: at least 2 cycles of PSMA-directed beta therapy; progression before cycle 3 excludes; more than 6 cycles excludes | June 2029 |
| PSMAcTION (Phase 2/3) | Novartis | AAA817, Ac-225-PSMA-617 | Metastatic castration-resistant prostate cancer | 443 planned | Required: progressed on or after Lu-177-PSMA | June 2028 |
| AcTFirst (Phase 3) | Novartis | AAA817 with or without ARPI | Metastatic castration-resistant prostate cancer | 940 planned | Excluded: prior radiopharmaceutical cancer therapy | September 2028 |
Source: ClinicalTrials.gov records NCT05477576, NCT07611110, NCT06780670, NCT06855277, read on 20 November 2026. Enrollment for VECTRA-01, PSMAcTION and AcTFirst is planned, not final.
Two details matter more than the headline count.
First, ACTION-1 does not simply enroll "patients who had Lu-177". It requires 2 to 4 cycles of a Lu-177 somatostatin analog, at least six months of disease control after it, and then progression. In other words, it enrolls patients whose disease stayed controlled for at least six months after Lu-177 and then progressed.
Second, VECTRA-01 requires at least two cycles of a PSMA-targeted beta therapy and excludes anyone who progressed before the third cycle. It also excludes patients who had more than six cycles, and requires prior taxane chemotherapy and an androgen receptor pathway inhibitor (ARPI). That is a narrow, late-line population, deliberately chosen.
The one readout so far
On 12 October 2026, BMS said ACTION-1 met its primary endpoint, progression-free survival by blinded independent central review, at a planned interim analysis. Patients were randomized to RYZ101 or investigator's choice of standard care (somatostatin analogs, everolimus or sunitinib). BMS did not publish a hazard ratio or other numbers, overall survival is still being followed, and detailed results are expected at a future medical meeting.
If it is approved on that design, the first Ac-225 radioligand label in neuroendocrine tumors would sit squarely after Lu-177.
Why "after beta" changes the commercial picture
Source: ClinicalTrials.gov records for AcTFirst, PSMAcTION and VECTRA-01. Pluvicto approval reported by Healio, 3 August 2026.
A drug approved after another drug inherits that drug's patient flow. Three consequences follow.
Beta therapy becomes the doorway. If the first Ac-225 labels follow these designs, prior beta treatment defines the potential patient pool. Whether that adds to Lu-177 demand depends on whether a later alpha option changes how early, and how widely, Lu-177 is prescribed.
The launch sites already exist. Centers that already deliver Lu-177 have the nuclear medicine teams, dose logistics and referral routes an Ac-225 launch needs, and are plausible first launch sites. Each would still need to confirm its authorization, handling procedures and dose supply for Ac-225. Developers who already sell into them start with relationships, data and contracts that newcomers have to build.
Lu-177 keeps moving earlier. Novartis reported Pluvicto sales of $674 million in the third quarter of 2026, up 20% at constant currency, and pointed to demand in metastatic hormone-sensitive prostate cancer. The FDA approved Pluvicto with an ARPI in PSMA-positive hormone-sensitive disease on 31 July 2026. More patients starting Lu-177 earlier could enlarge the pool for a later alpha.
Only some will reach it still eligible. VECTRA-01's cap of six prior beta cycles and its taxane requirement would exclude some long-term Pluvicto responders, and earlier Pluvicto use removes patients from AcTFirst's population altogether. Sales growth also measures revenue, not patient numbers. The direction looks clear, and the size of the effect is still uncertain.

The fourth trial
AcTFirst is the outlier, and the most interesting.
It is the largest of the four at 940 patients planned. It enrolls men with castration-resistant prostate cancer who progressed on their last ARPI in the hormone-sensitive or earlier setting and have had no taxane chemotherapy for castration-resistant disease. It excludes anyone who has had a radiopharmaceutical as cancer treatment, including Lu-177-PSMA. Patients are randomized to AAA817 with an ARPI, AAA817 alone, or the investigator's choice of standard care: an ARPI change, taxane chemotherapy, or AAA617, which is Pluvicto.
So the largest of the four, and the one testing Ac-225 in patients who have not had beta therapy, is run by the company that sells the leading beta therapy, and its control arm can include that beta therapy.
It is worth being precise about what AcTFirst can show. A win against a pooled investigator's-choice arm would not by itself establish superiority over Pluvicto. Primary completion is estimated for September 2028.
Meanwhile, PSMAcTION tests the same molecule after Lu-177-PSMA. Novartis is testing AAA817 in both sequences at once.
The timeline to watch
Source: ClinicalTrials.gov, BioPharm International (12 October 2026) and Healio (3 August 2026).
- ACTION-1: full data at a medical meeting, then the regulatory path BMS agrees with the FDA. Overall survival is the number everyone will want.
- PSMAcTION: estimated primary completion June 2028.
- AcTFirst: estimated primary completion September 2028. This is the most important readout for whether alpha can move earlier in prostate cancer, though a win against a pooled comparator arm would not by itself show superiority over Pluvicto.
- VECTRA-01: started in May 2026, estimated primary completion June 2029, across 151 listed sites in 24 countries.
What could prove this wrong
Four things would change this view:
- Head-to-head data. Smaller studies already compare the two isotopes directly. UCLA's randomized Phase 2 ANDROMEDA trial (107 patients planned, started December 2025) compares two cycles of Lu-177-PSMA-617 with one cycle of Ac-225-PSMA-617 in oligorecurrent prostate cancer; both groups then receive metastasis-directed stereotactic body radiotherapy. Strong alpha results in earlier disease would strengthen the case for moving up.
- AcTFirst winning clearly, especially in patients whose comparator was Pluvicto.
- Earlier-line Ac-225 trials from other sponsors. Several earlier-phase Ac-225 programs enroll patients who have never had PSMA radioligand therapy (Lilly's Ac-225-PSMA-62 study, for example, excludes castration-resistant patients who have had PSMA radioligand therapy). If they move into Phase 3 in that setting, the "after beta" pattern weakens.
- Safety. Tolerability data from the Phase 3s will shape how early clinicians are willing to use alpha therapy.
ProGen reading
Our reading is that the first Ac-225 radioligand label comes after Lu-177, and that for the rest of this decade alpha adds to the Lu-177 market before it eats into it. We would be wary of any forecast that assumes Lu-177 demand peaks the moment an alpha drug launches.
The most valuable asset for an early alpha launch looks like a steady flow of patients coming off beta therapy, and the treating centers that manage them. Novartis already sells Pluvicto and Lutathera into those centers. BMS and AstraZeneca will need to win it, through partnerships, referral networks and medical affairs coverage of those centers.
And by testing AAA817 both after Lu-177 and in patients who could otherwise receive Pluvicto, Novartis looks positioned to come out ahead whichever sequence wins.
For Lu-177 suppliers and manufacturers, this reads as continued demand through the first alpha launches. For anyone building an Ac-225 launch, the question to answer early is how you reach patients who are already being treated with Lu-177.
Forward-looking statements in this article are ProGen's interpretation of public information and are not investment advice.
FAQ
How many Ac-225 radioligand trials have a Phase 3 component?
We found four on ClinicalTrials.gov as of 20 November 2026: ACTION-1 (RYZ101), VECTRA-01 (AZD2265), PSMAcTION (AAA817) and AcTFirst (AAA817). Two include an earlier phase in the same study (ACTION-1 is Phase 1b/3; PSMAcTION is Phase 2/3).
Do Ac-225 Phase 3 trials require prior Lu-177 therapy?
Three of the four enroll patients after beta therapy: ACTION-1 requires prior Lu-177 somatostatin analog treatment, PSMAcTION requires progression on or after Lu-177-PSMA, and VECTRA-01 requires at least two cycles of a PSMA-directed beta therapy. AcTFirst excludes prior radiopharmaceutical treatment.
What did the ACTION-1 trial show?
BMS reported on 12 October 2026 that ACTION-1 met its primary endpoint of progression-free survival at a planned interim analysis in neuroendocrine tumors that progressed after Lu-177 therapy. No effect size was published in the announcement.
Is Ac-225 being compared directly with Pluvicto?
AcTFirst's control arm is investigator's choice and can include Pluvicto (AAA617), alongside an ARPI change or taxane chemotherapy. UCLA's randomized Phase 2 ANDROMEDA trial compares two cycles of Lu-177-PSMA-617 with one cycle of Ac-225-PSMA-617 in oligorecurrent prostate cancer, both followed by stereotactic body radiotherapy.
About this intelligence
This analysis draws on public trial registries, company announcements and regulatory disclosures, together with proprietary ProGen sources. Facts are linked to their sources below; interpretation is labeled "ProGen reading". Information is current as of 20 November 2026.
Sources
- ClinicalTrials.gov, NCT05477576 (ACTION-1)
- ClinicalTrials.gov, NCT07611110 (VECTRA-01)
- ClinicalTrials.gov, NCT06780670 (PSMAcTION)
- ClinicalTrials.gov, NCT06855277 (AcTFirst)
- ClinicalTrials.gov, NCT07150715 (ANDROMEDA)
- BioPharm International, RYZ101 ACTION-1 meets primary endpoint (12 October 2026)
- Novartis, Q3 2026 results (27 October 2026)
- Healio, FDA approves Pluvicto for PSMA-positive metastatic hormone-sensitive prostate cancer (3 August 2026)
Other sources are proprietary ProGen intelligence sources.